structures human phosphofructokinase- atomic basis cancer-associated mutations 
phosphofructokinase- pfk1 gatekeeper glycolysis catalyses committed step glycolytic pathway converting fructose--phosphate fructose--bisphosphate allosteric activation inhibition pfk1 ten metabolites response hormonal signalling fine-tune glycolytic flux meet energy requirements1 mutations inhibiting pfk1 activity cause glycogen storage disease type vii also known tarui disease2 mice deficient muscle pfk1 decreased fat stores3 additionally pfk1 proposed important roles metabolic reprogramming cancer45 despite critical role glucose flux biologically relevant crystal structure mammalian pfk1 tetramer determined report first structures mammalian pfk1 tetramer human platelet isoform pfkp complex atp-mg2+ adp angstrom respectively structures reveal substantial conformational changes enzyme upon nucleotide hydrolysis well unique tetramer interface mutations residues interface can affect tetramer formation enzyme catalysis regulation indicating functional importance tetramer altered glycolytic flux hallmark cancers6 new structures allow molecular understanding functional consequences somatic pfk1 mutations identified human cancers characterize three mutations show distinct effects allosteric regulation pfkp activity lactate production pfkp structural blueprint somatic mutations well catalytic site can guide therapeutic targeting pfk1 activity control dysregulated glycolysis disease 
